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Clinical and epidemiological research

Efficacy and safety of abatacept, a T-cell modulator,
in a randomised, double-blind, placebo-controlled,
phase III study in psoriatic arthritis
Philip J Mease,1 Alice B Gottlieb,2 Désirée van der Heijde,3 Oliver FitzGerald,4
Alyssa Johnsen,5 Marleen Nys,6 Subhashis Banerjee,5 Dafna D Gladman7
ABSTRACT
Objectives To assess the efficacy and safety of
abatacept, a selective T-cell costimulation modulator, in a
phase III study in psoriatic arthritis (PsA).
Methods This study randomised patients (1:1) with
1
Swedish Medical Center and
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Results Abatacept significantly increased ACR20
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response rates (reduction from baseline ≥0.35) at
week 24, this was not statistically significant (31.0%
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the benefit on psoriasis lesions was modest. Efficacy was
maintained or improved up to week 52. Abatacept was
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well tolerated with no new safety signals.
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Conclusions Abatacept treatment of PsA in this phase
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III study achieved its primary end point, ACR20 response,
4 May 2017
showed beneficial trends overall in musculoskeletal
manifestations and was well tolerated. There was only a
modest impact on psoriasis lesions.
Trial registration number ClinicalTrials.gov number,
NCT01860976 (funded by Bristol-Myers Squibb).

►► Additional material is
published online only. To view
please visit the journal online
(http://d x.doi.o rg/10.1136/
annrheumdis-2016-210724).
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Psoriatic arthritis (PsA) is an inflammatory arthritis
that occurs in up to one-third of patients with
psoriasis and is usually diagnosed years after the
appearance of psoriatic skin disease.1 2 Although
current treatments for PsA benefit many patients,
a substantial proportion do not achieve significant
improvement in their disease.3–5 Consequently,
there remains an unmet need for effective and
well-tolerated treatments.
PsA is associated with specific major histocompatibility complex class I molecules that are
involved in antigen presentation to T cells, which

are implicated in disease pathogenesis.6 Abatacept,
a selective T-cell costimulation modulator, is a
soluble fusion protein comprising the extracellular
domain of human cytotoxic T-lymphocyte-associated antigen-4 linked to the modified Fc (hinge,
CH2 and CH3 domains) portion of human immunoglobulin G1.7 8 By selectively modulating the
CD28 costimulatory signal required for full T-cell
activation, abatacept blocks the process that triggers the inflammatory cascade and, therefore, is a
potential therapy for PsA with a distinct mechanism
of action upstream of currently available agents.4 7
Abatacept is an approved treatment for rheumatoid
arthritis (RA) and juvenile idiopathic arthritis, with
an established acceptable safety profile.9–14
Data have previously been reported from a phase
II, dose-ranging study of abatacept in patients with
active PsA and prior exposure to disease-modifying
antirheumatic drugs (DMARDs), 37% of whom
had previously received tumour necrosis factor
inhibitor (TNFi). At 6 months, the dose of 10 mg/
kg given intravenously every 4 weeks showed the
greatest increase in the proportion of patients with
≥20% improvement in the American College of
Rheumatology criteria (ACR20) versus placebo
(48% vs 19%, respectively; p=0.006).15 The
proportion of patients achieving a Health Assessment Questionnaire–Disability Index (HAQ-DI)
response (reduction from baseline score ≥0.3)
at 6 months was also increased in the 10 mg/kg
group versus placebo (45% vs 19%, respectively).
In addition, trends towards improvements over
placebo were seen in joint damage, based on MRI.
Following these results, the phase III Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) Study
was conducted to assess the efficacy and safety of
abatacept in patients with active PsA, using a more
convenient subcutaneous 125 mg weekly dose that
has shown therapeutic equivalence to intravenous dosing with 10 mg/kg every 4 weeks in RA.16

Methods
Study design and oversight

This ongoing phase III study (total study duration including long-term extension, 729 days)
was initiated in June 2013 and conducted across
76 centres worldwide (
ClinicalTrials.
gov number,
NCT01860976). Clinical and radiographic database
locks were in August and October 2015 (24-week
analysis) and in March and April 2016 (1-year analysis), respectively. Using a central interactive voice

Mease PJ, et al. Ann Rheum Dis 2017;76:1550–1558. doi:10.1136/annrheumdis-2016-210724

Ann Rheum Dis: first published as 10.1136/annrheumdis-2016-210724 on 4 May 2017. Downloaded from http://ard.bmj.com/ on 29 June 2018 by guest. Protected by copyright.

Extended report

Clinical and epidemiological research

Patients

Enrolled patients were aged ≥18 years, met the classification criteria for PsA17 and had active arthritis (≥3 swollen
and ≥3 tender joints), active plaque psoriasis with ≥1 qualifying target lesion ≥2 cm in diameter and inadequate response
or intolerance to ≥1 non-biologic DMARD. Concomitant treatment with methotrexate, leflunomide, sulfasalazine or hydroxychloroquine, non-steroidal anti-inflammatory drugs and oral
corticosteroids (<10 mg/day) and use of low-potency topical
corticosteroids in sensitive areas were permitted (as detailed
in online section 1 in the supplementary appendix). To reflect
a typical patient population in clinical practice and that of the
phase II study,15 both TNFi-naïve and TNFi-exposed patients
were enrolled. All patients gave written informed consent prior
to study entry.

Assessments

Arthritis was assessed in 66 joints for swelling and 68 joints
for tenderness by ACR response criteria for per cent improvement from baseline18 and post hoc by the Disease Activity Score
(DAS)28 (C-reactive protein (CRP)).19 Enthesitis at six locations was evaluated using the Leeds Enthesitis Index (range
0–6)20 and dactylitis by the number of tender and swollen digits
with a circumference ≥10% greater than the contralateral digit
according to the Leeds Dactylitis Index basic score.21 Physical
function was measured using the HAQ-DI (range 0–3).22 Among
patients with plaque psoriasis involving ≥3% BSA at baseline,
skin lesions were assessed using the Psoriasis Area and Severity
Index (PASI; range 0–72).23 PsA disease activity was assessed
using the minimal disease activity (MDA) criteria,24 the modified Composite Psoriatic Disease Activity Index,25 the Psoriatic
Arthritis Disease Activity Score26 and post hoc for the Disease
Activity index for Psoriatic Arthritis (DAPSA).27 Quality of life
was evaluated using the Short Form-36 (SF-36)28 and the Dermatology Life Quality Index.29
Plain radiographs of hands and feet were taken at baseline and
at weeks 24 and 52 (or weeks 16, 24 and 44 for EE patients).
Radiographs were scored independently by two central, trained

assessors (and an adjudicator in predefined cases) with experience using the PsA-modified Sharp–van der Heijde (SHS) scoring
method (total score 0–528).30 Assessors were blinded to patient
identity, treatment, clinical data and order of radiographs.
Initially, baseline and week 24 (week 16 for EE) radiographs
were scored; in a second round, all radiographs, including week
52 (week 44 for EE), were scored. For joint erosion, joint space
narrowing and total score, and the proportion of non-progressors, the mean of the scores from two assessors was used. If one
score was missing, then the available score was used. If required,
an adjudicator reviewed the images, and the mean of the adjudicator’s total score and the other total score that was closer to the
adjudicator’s score was used (>0=progressors, ≤0=non-progressors). Safety was evaluated throughout the study by monitoring of adverse events (AEs) and routine laboratory tests.

Efficacy end points

The primary end point was the proportion of patients with
ACR20 responses at week 24. Key secondary end points at
week 24, in hierarchical order, were the proportions of patients
with an HAQ-DI response (reduction from baseline, ≥0.35),
an ACR20 response in the TNFi-naïve and TNFi-exposed
subgroups and a radiographic non-progression (change from
baseline score, ≤0) according to PsA-modified total SHS score.
Other secondary end points at week 24 included the proportion of patients with ≥50% and ≥70% improvement in ACR
criteria (ACR50 and ACR70, respectively), the proportion who
achieved ≥50% improvement in PASI score from baseline (PASI
50) and the mean change from baseline in SF-36 physical and
mental component summary scores. Prespecified exploratory
end points and post hoc analyses are described in online section
2 in the supplementary appendix.

Statistical analysis

A hierarchical testing procedure (ie, testing outcomes in a
predefined order) was used for the primary and key secondary
end points to ensure preservation of the overall type I error. All
estimates used for the sample size determination were based on
the results of the phase II study of abatacept in PsA,15 except for
non-progressors using PsA-modified total SHS score. A two-sided
continuity corrected χ2 test at alpha=0.05 was used. To achieve
≥80% power for each of the hierarchical end points and PASI
50 responders, recruitment of 400 patients was required: 152
(38%) and 248 (62%) in the TNFi-naïve and TNFi-exposed
subgroups, respectively (see online section 3 in the supplementary appendix).
All efficacy analyses (including those up to week 44 or 52)
were conducted using the intent-to-treat (ITT) population,
which comprised all randomised patients who received at least
one dose of study medication. Comparisons between treatment arms were performed for the primary and key secondary
end points, and PASI 50 responders at week 24, using a
two-sided Cochran-Mantel-Haenszel χ2 test, stratified by
current methotrexate use, prior TNFi use and plaque psoriasis
involving ≥3% of BSA, at a 5% significance level for generating p values. The p values that did not control for overall type
I error (nominal p values) were provided for end points that
ranked lower in the statistical hierarchy than the first end point
that was non-statistically significant at the 5% level, and for
PASI 50 response, MDA and DAPSA score at week 24. For other
end points, only 95% CIs of differences between abatacept and
placebo arms were generated without obtaining p values. For
binary responder analyses during the double-blind period, EE
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response system, patients were randomly assigned (1:1) in a
double-blind manner to receive subcutaneous abatacept 125 mg
weekly or matched placebo for 24 weeks. Randomisation was
stratified globally (rather than at site level) by factors that were
considered to potentially impact results, including current
methotrexate use, prior TNFi use and whether plaque psoriasis
involved ≥3% of body surface area (BSA). Within each stratum,
permuted block randomisation was conducted with a block size
of two. Patients who had not achieved ≥20% improvement in
swollen and tender joint counts from baseline to week 16 were
switched to open-label abatacept weekly (early escape (EE))
for 28 weeks (total study time for these patients, 44 weeks). At
week 24, all remaining patients transitioned to the open-label
period and received subcutaneous abatacept weekly for 28 weeks
(total study time, 52 weeks). At the end of the open-label period,
patients had the option of entering a 1-year, long-term extension.
The study was conducted in accordance with the Declaration
of Helsinki, International Conference on Harmonisation Guidelines for Good Clinical Practice and local regulations. An Institutional Review Board or Independent Ethics Committee approved
the protocol, consent form and any other written information
provided to patients. Patients were evaluated by the investigators, and the data were collected and analysed by Bristol-Myers
Squibb under the direction of the investigators.

Clinical and epidemiological research

Results
Patients
In total, 424 randomised patients received at least one dose of
abatacept (n=213) or placebo (n=211). Patient characteristics
at baseline are shown in table 1. The overall mean (SD) age was
50.4 (11.0) years, 55% were female and 60% reported current
methotrexate use, with a mean (SD) dose of 17.1 (8.2) mg/
week at baseline. Most patients (~60%) had previously received
TNFi agents; of these, most (abatacept 60%, placebo 62%) had
failed at least one TNFi due to inadequate efficacy. Overall, 69%
of patients had psoriasis covering ≥3% of BSA. Numbers of
non-biologic DMARDs used prior to study entry are described
in online table 1 in the supplementary appendix. The baseline
disease characteristics included mean (SD) disease duration of
8.5 (8.2) years; distal interphalangeal involvement in approximately half of the population (50.7%); presence of joint erosion
on radiographs in 84% of patients, with a mean (SD) PsA-modified total SHS score of 18.8 (43.3); elevated serum CRP above
upper limit of normal (3 mg/L) in 66% of patients, with a mean
(SD) CRP of 14.1 (25.9) mg/L; and polyarticular disease in 98%
of patients, with mean (SD) tender and swollen joint counts of
20.2 (13.3) and 11.6 (7.5), respectively.
Patient disposition is shown in figure 1. A total of 76 (35.7%)
and 89 (42.2%) patients in the abatacept and placebo groups,
respectively, were assigned to EE and switched to open-label
abatacept at week 16. From the original abatacept and placebo
arms, 197 (92.5%) and 185 (87.7%) patients, respectively,
entered the open-label period.
1552

Musculoskeletal manifestations
Arthritis

Abatacept treatment resulted in a significantly higher proportion of patients achieving an ACR20 response at week 24 versus
placebo (39.4% vs 22.3%; p<0.001; table 2; figure 2; online
table 2 in the supplementary appendix). The mean change from
baseline in each of the ACR core components was numerically
greater for patients in the abatacept group than those in the
placebo group at 24 weeks (see online table 3 in the supplementary appendix).
As the effect of abatacept on the first key secondary end point
in the statistical hierarchy (HAQ-DI response rate) did not reach
significance (see below), only nominal p values were generated
for subsequent outcomes. Nominally higher ACR20 response
rates with abatacept versus placebo were seen in both TNFinaïve and TNFi-exposed subgroups at week 24 (table 2), with
the largest treatment difference seen in TNFi-naïve patients.
ACR20 responses at 24 weeks by number of prior TNFi received
are shown in online table 4 in the supplementary appendix.
Analysis (ITT population) up to week 44 showed that ACR20
responses were maintained for patients who continued abatacept
and improved for those who switched from placebo to abatacept
(placebo/abatacept) in the total population and in both TNFinaïve and TNFi-exposed subgroups (table 2; figure 3; online
table 5 in the supplementary appendix). Because the trial design
allowed for early escape to open-label abatacept, improvement
in the placebo-treated patients initiating active treatment would
be expected starting at week 16. Similar trends were observed
for ACR50 and ACR70 responses (table 2). In addition, patients
with CRP elevated above the upper limit of normal at baseline
showed the highest ACR20 responses at 24 weeks with abatacept treatment versus placebo (estimated differences (95% CI)):
total population, 43.8% versus 23.7% (20.17 (9.32 to 31.02));
TNFi naïve, 50.0% versus 23.9% (26.09 (7.93 to 44.25)); TNFi
exposed, 40.2% versus 23.5% (16.69 (3.21 to 30.17)).
The efficacy of abatacept in reducing arthritic manifestations
was supported by the results of the post hoc analysis of greater
improvement in DAS28 (CRP) from baseline to week 24 with
abatacept versus placebo: adjusted mean change, –1.35 versus
–0.94; adjusted difference (95% CI), –0.42 (–0.69 to –0.14).
Continued improvement beyond week 24 in the ITT population was seen in adjusted mean changes from baseline in DAS28
(CRP) in both abatacept and placebo/abatacept groups, with
changes from baseline to week 44 of –1.81 and –1.84, respectively (see online supplementary figure 1 and table 6 in the
supplementary appendix).

Enthesitis and dactylitis

At week 24, complete resolution of enthesitis and dactylitis
present at baseline was numerically more frequent with abatacept versus placebo. The proportions (95% CI) of patients with
enthesitis resolution were 32.9% (25.1 to 40.6) versus 21.2%
(14.2 to 28.2) and with dactylitis resolution were 44.3% (31.8
to 56.7) versus 34.0% (20.9 to 47.1), respectively. At week
44/52, an increased proportion of patients achieved complete
resolution of baseline enthesitis (48.6% vs 43.9%) and dactylitis
(68.9% vs 60.0%) in both the abatacept and placebo/abatacept
groups, respectively.

Physical function

The proportion of patients with an HAQ-DI response (reduction from baseline score ≥0.35) at week 24 was numerically
higher with abatacept versus placebo: 31.0% versus 23.7%;
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patients at week 16 were imputed as non-responders at weeks
20 and 24 (for radiographic analysis, EE patients were imputed
as progressors at week 24). Patients who discontinued treatment
were imputed as non-responders/radiographic progressors at all
subsequent visits. Continuous variables for the double-blind
analysis were assessed using a longitudinal repeated-measures
analysis, imputing EE patients as missing beyond week 16 (see
online section 3 in the supplementary appendix). In addition,
if there were still missing data (for EE patients between week 4
and week 16 and for non-EE patients between week 4 and week
24), patients were imputed as non-responders at the time point
with missing data. However, if data were missing between two
time points at which the patient had a response (eg, ACR20),
then in such cases the response (eg, ACR20) was imputed at the
time point with missing data.
Analyses up to week 44/52 used actual data at each time
point for EE and non-EE patients. A non-responder imputation
was done for all missing values regardless of escape status. As
mentioned above, the denominators for all responder analyses up
to week 44/52 were equal to all randomised and treated patients
(ITT population). Most efficacy end points are reported only up
to week 44, at which time EE patients had received 28 weeks and
non-EE patients had received 20 weeks of open-label treatment.
However, for analyses of enthesitis, dactylitis and radiographic
data, week 44 data from EE patients were combined with week
52 data from non-EE patients, as these data were not collected
at week 44 for non-EE patients. Continuous variables were analysed for this period using the longitudinal repeated-measures
analysis model using the actual data including all patients in the
ITT population. For SHS scores, adjusted mean change from
baseline up to week 44/52 was calculated using the longitudinal
repeated measures analysis model with the actual values for EE
and non-EE patients (ITT population).

Clinical and epidemiological research
Patient characteristics at baseline
Abatacept (n=213*)

Placebo (n=211*)

Demographic characteristics
Age, years

51.0 (10.7)

Sex, female, n (%)

121 (56.8)

49.8 (11.3)
112 (53.1)

Race, white, n (%)

195 (91.5)

198 (93.8)

Body mass index, kg/m2

30.7 (6.3)

31.3 (6.8)

Region, n (%)
South America

95 (44.6)

80 (37.9)

Europe

53 (24.9)

59 (28.0)

North America

44 (20.7)

40 (19.0)

Rest of World

21 (9.9)

32 (15.2)

Disease characteristics
  8.3 (8.1)

PsA duration, years

  8.8 (8.3)

TJC

21.0 (13.4)

19.3 (13.1)

SJC

12.1 (7.8)

11.1 (7.2)

DIP involvement,† n (%)

114 (53.5)
  1.3 (0.7)

HAQ-DI

101 (47.9)
  1.3 (0.7)

Patient Global Assessment of disease activity (VAS 0–100 mm)

61.1 (23.5)

62.6 (22.6)

Physician Global Assessment of disease activity (VAS 0–100 mm)

53.9 (18.8)

55.0 (19.6)

Patient Global Assessment of pain (VAS 0–100 mm)

64.2 (23.5)

64.4 (21.8)

CRP, mg/L

14.0 (20.9)

14.3 (30.3)

Elevated CRP (>ULN‡), n (%)

146 (68.9)
  5.0 (1.1)

DAS28 (CRP)
PsA-modified total SHS

20.0 (46.8)

Psoriasis covering ≥3% BSA, n (%)§

146 (68.5)
  7.4 (8.0)

PASI score¶**

131 (62.7)
  4.9 (1.1)
17.7 (39.6)
148 (70.1)
  7.2 (7.8)

Enthesitis, n (%)

140 (65.7)

Dactylitis, n (%)

61 (28.6)

132 (62.6)

Anti-CCP positive (>10 U/mL), n (%)

10 (5.1)

  2 (1.0)

129 (60.6)

130 (61.6)

50 (23.7)

Medication use
Prior TNFi, n (%)
1

94 (44.1)

92 (43.6)

2

31 (14.6)

36 (17.1)

≥3

  4 (1.9)

  2 (0.9)

Concomitant methotrexate, n (%)

129 (60.6)

127 (60.2)

Concomitant csDMARDs other than methotrexate, n (%)

27 (12.7)

25 (11.8)

Concomitant oral corticosteroids, n (%)**

56 (26.3)

51 (24.2)

Data are presented as mean (SD) unless indicated otherwise.
*For the following assessments, patient numbers in the abatacept and placebo arms, respectively, were as follows: body mass index (212 and 210), HAQ-DI score (212 and 211),
Patient Global Assessment of disease activity (211 and 210), Physician Global Assessment of disease activity (210 and 209), Patient Global Assessment of pain (213 and 210),
elevated CRP (212 and 209), DAS28 (CRP) score (210 and 208), PsA-modified total SHS score (205 and 202), PASI score (145 and 148) and anti-CCP positive (196 and 198).
†One or more swollen or tender DIP joint.
‡ULN=3 mg/L.
§Of patients with psoriasis covering ≥3% of BSA in the abatacept and placebo arms, 55 and 51 were in the TNFi-naïve subgroup, and 91 and 97 were in the TNFi-exposed
subgroup, respectively.
¶Measured only for patients with psoriasis covering ≥3% of BSA.
**Mean (SD) oral daily steroid dose at baseline (prednisone equivalent) abatacept, 6.8 (2.68); placebo, 6.3 (2.56).
BSA, body surface area; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28 (CRP), Disease
Activity Score 28 (C-reactive protein); DIP, distal interphalangeal; HAQ-DI, Health Assessment Questionnaire–Disability Index (range 0–3); PASI, Psoriasis Area and Severity Index
(range 0–72); PsA, psoriatic arthritis; PsA-modified total SHS, psoriatic arthritis-modified total Sharp/van der Heijde score (range 0–528); SJC, swollen joint count (range 0–66);
TJC, tender joint count (range 0–68); TNFi, tumour necrosis factor inhibitor; ULN, upper limit of normal; VAS, visual analogue scale.

estimated difference (95% CI), 7.2 (–1.1 to 15.6); p=0.097.
However, as this did not reach statistical significance, only
nominal p values were generated for lower-ranking end points
in the hierarchical testing. HAQ-DI responses at 24 weeks in
the abatacept versus placebo arms were 34.5% versus 19.8%,
respectively, in the TNFi-naïve subgroup (estimated difference
14.8; 95% CI 1.7 to 28.0) and 28.7% versus 26.2%, respectively, in the TNFi-exposed subgroup (estimated difference 2.5;
95% CI –8.3 to 13.3). HAQ-DI responses were maintained to

week 44 in the abatacept group and improved in the placebo/
abatacept group (39.9% and 38.9%, respectively) in the ITT
population.
Further analyses showed nominal improvements in adjusted
mean change in HAQ-DI score from baseline to week 24 with
abatacept versus placebo for all patients: –0.33 versus –0.20,
respectively; estimated difference (95% CI), –0.13 (–0.25 to
–0.01), and in both TNFi-naïve (–0.29 vs –0.17) and TNFi-exposed (–0.35 vs –0.18) subgroups. Continued improvements
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Table 1

Clinical and epidemiological research

were seen in the total population and TNFi-naïve and TNFi-exposed subgroups at week 44 in the ITT analyses (see online
supplementary figure 2 and table 7 in the supplementary
appendix).

Structural damage

The proportion of patients without radiographic progression
at week 24 was 42.7% in the abatacept group versus 32.7% in
the placebo group (estimated difference (95% CI), 10.0 (1.0 to
19.1); nominal p=0.034). The mean (SE) change from baseline
in PsA-modified total SHS score was 0.30 (0.12) versus 0.35
(0.13) at week 24 for abatacept versus placebo and 0.18 (0.12)
versus 0.30 (0.12) at week 44/52 for abatacept versus placebo/
abatacept.

Table 2

Psoriatic skin responses
The psoriatic skin response was more modest compared with
the musculoskeletal response. At week 24, there was a small
numerical increase in the proportion of PASI 50 responders
with abatacept compared with placebo: 26.7% versus 19.6%
(estimated difference (95% CI), 7.3 (–2.2 to 16.7); nominal
p=0.137). The proportion of patients with ≥75% improvement in PASI score from baseline (PASI 75 responders) with
abatacept versus placebo at week 24 was 16.4% versus 10.1%,
respectively.
The magnitude of improvement in both PASI 50 and PASI
75 response rates with abatacept versus placebo at week 24
was numerically greater in the TNFi-naïve compared with the
TNFi-exposed subgroup: PASI 50 (TNF naïve, 32.7% vs 19.6%;

ACR20/50/70 responders in the total population and TNFi-naïve and TNFi-exposed subgroups (ITT population)
Week 24
Abatacept

Week 44
Placebo

Estimated difference
(95% CI)

Abatacept/open-label
abatacept

Placebo/open-label
abatacept

n=213

n=211

17.2 (8.7 to 25.6)*

48.4

49.3

Total population

n=213

n=211

ACR20

39.4

22.3

ACR50

19.2

12.3

6.9 (0.1 to 13.7)

28.2

32.2

ACR70

10.3

6.6

3.7 (–1.5 to 8.9)

15.5

17.5

n=84

n=81

54.8

56.8

TNFi naïve

n=84

n=81

ACR20

44.0

22.2

21.9 (8.3 to 35.6)†

ACR50

25.0

14.8

10.2 (–1.5 to 22.0)

35.7

38.3

ACR70

11.9

8.6

3.3 (–5.8 to 12.4)

14.3

23.5

n=129

n=130

14.0 (3.3 to 24.8)‡

44.2

44.6

TNFi exposed

n=129

n=130

ACR20

36.4

22.3

ACR50

15.5

10.8

4.7 (–3.4 to 12.8)

23.3

28.5

ACR70

9.3

5.4

3.9 (–2.4 to 10.2)

16.3

13.8

Data are presented as percentages of patients.
Early escape patients were imputed as non-responders in the week 24 analysis. Estimated differences between original treatment arms were not calculated in the week 44
analysis.
*p<0.001 versus placebo.
†Nominal p=0.003 versus placebo.
‡Nominal p=0.012 versus placebo.
ACR20, ≥20% improvement in American College of Rheumatology criteria; ACR50, ≥50% improvement in American College of Rheumatology criteria; ACR70, ≥70%
improvement in American College of Rheumatology criteria; ITT, intent-to-treat; TNFi, tumour necrosis factor inhibitor.
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Figure 1 Patient disposition. SC, subcutaneous. *Includes missing (n=2).
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TNFi exposed, 23.1% vs 19.6%) and PASI 75 (TNFi naïve,
18.2% vs 9.8%; TNFi exposed, 16.5% vs 10.3%).
In the ITT population at week 44, PASI 50 response rates
were maintained for patients who continued on abatacept (total
population, 30.1%; TNFi naïve, 36.4%; TNFi exposed, 26.4%)
and improved for those who switched from placebo to abatacept
(total population, 34.5%; TNFi naïve, 39.2%; TNFi exposed,
32.0%). PASI 75 responses were also maintained for patients
who continued on abatacept (total population, 19.9%; TNFi
naïve, 27.3%; TNFi exposed, 15.4%) and improved for the
placebo/abatacept group (total population, 16.9%; TNFi naïve,
17.6%; TNFi exposed, 16.5%).

Disease activity—composite measures

The proportion of patients with MDA at week 24 was numerically higher with abatacept versus placebo in the total population
(11.7% vs 8.1%; nominal p=0.205). At week 52, the proportion of patients with MDA increased to 17.4% for patients who
continued on abatacept and 18.5% for the placebo/abatacept
group. Similar trends were observed in the modified Composite
Psoriatic Disease Activity Index and Psoriatic Arthritis Disease
Activity Score (see online section 4 in the supplementary
appendix). There was a nominally significant improvement with
abatacept versus placebo in adjusted mean change from baseline to week 24 in DAPSA score (–18.75 vs –13.00; adjusted
difference –5.75; 95% CI –10.01 to –1.49; nominal p=0.008).
At week 44, further improvements in adjusted mean change
from baseline in DAPSA score were observed in the abatacept
and placebo/abatacept groups (–24.58 and –25.18, respectively).

Quality of life

At 24 weeks, mean improvements from baseline were numerically
greater with abatacept versus placebo for SF-36 physical component summary and Dermatology Life Quality Index scores but
were similar between the two groups for SF-36 mental component summary scores. Similar results were also seen at week 52
(see online table 8 in the supplementary appendix).

Safety

Safety findings during the 24-week, double-blind period and for
cumulative abatacept treatment over the 52-week study period
are summarised in table 3. During the 24-week, double-blind
period, the abatacept and placebo groups had similar safety
profiles, with comparable incidences, respectively, of serious AEs
(2.8% vs 4.3%), AEs (54.5% vs 53.1%) and infections (26.8%
vs 29.9%). One serious infection (Pneumocystis jirovecii) was
considered related to study drug by the investigator and led
to treatment discontinuation. This event occurred during the
double-blind period in a patient receiving abatacept who had a
history of smoking and chronic obstructive pulmonary disease
and had recently used high-dose corticosteroids. The episode
resolved after 7 days of appropriate treatment.

Discussion

In this phase III study, selective modulation of T-cell costimulation with abatacept resulted in significantly higher ACR20
response rates in patients with PsA compared with placebo, with
responses maintained to at least 1 year. Our findings support
previous data suggesting a role for T cells in PsA: activated T
cells are abundant in the synovial fluid of patients with PsA31 32
and frequencies of interleukin (IL)-17-secreting CD8+ T cells
are increased in erosive disease.32 Furthermore, treatment with
abatacept has been shown to reduce circulating IL-17-secreting
CD4+ and CD8+ T cells in RA.33 The data reported here
suggest that selective inhibition of the CD28-dependent costimulatory pathway critical for T-cell activation7 may offer a novel
treatment option in PsA.
Our findings demonstrate that abatacept had an overall beneficial effect on musculoskeletal symptoms and was well tolerated in a relatively refractory population of patients with PsA
(approximately 60% had received prior TNFi), confirming
earlier results from a phase II, dose-ranging study in a less refractory population (approximately 30% of patients in the abatacept 10 mg/kg and placebo groups had received prior TNFi).15
The primary end point was met, with a statistically significantly
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Figure 2 ACR20 response over the 24-week double-blind period (non-responder imputation for early escape). Early escape patients switching to
open-label abatacept at week 16 were imputed as non-responders at weeks 20 and 24. If there were still missing data, patients were imputed as nonresponders, unless data were missing between two time points at which the patient had a response, in which case response was imputed. #Where
95% CI of estimate of differences in ACR20 responses for abatacept versus placebo do not contain zero. ACR20, ≥20% improvement in the American
College of Rheumatology criteria.
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Summary of safety
Double-blind period*

Week 52†

Abatacept
(n=213)

Placebo
(n=211)

Cumulative abatacept
population (n=398)

Deaths

  0

  0

  0

SAEs

  6 (2.8)

  9 (4.3)

34 (8.5)

Treatment related

  1 (0.5)‡

  1 (0.5)

  5 (1.3)§

Leading to discontinuation   3 (1.4)

  3 (1.4)

  8 (2.0)¶

AEs

116 (54.5)

112 (53.1)

273 (68.6)

33 (15.5)

24 (11.4)

81 (20.4)

Treatment related

Leading to discontinuation   3 (1.4)

  4 (1.9)

13 (3.3)

AEs reported in ≥5% of
patients
Nasopharyngitis

  9 (4.2)

11 (5.2)

25 (6.3)

Upper RTI

  6 (2.8)

14 (6.6)

28 (7.0)

Bronchitis

  7 (3.3)

  5 (2.4)

26 (6.5)

AEs of special interest
Infections

57 (26.8)

63 (29.9)

162 (40.7)

Malignancies

  0

  2 (0.9)

  4 (1.0)

Autoimmune events

  0

  0

  1 (0.3)

Local ISRs

  1 (0.5)

  1 (0.5)

  5 (1.3)

Data are presented as n (%) of patients.
Investigators were instructed not to report psoriasis or psoriatic arthritis as AEs
unless they were new forms of psoriasis or SAEs.
*Includes data up to 56 days after the last dose in the double-blind period or the
first dose in the open-label period, whichever occurred first.
†Includes data from the first day of the double-blind period for patients in the
abatacept group and from the first day of the open-label period for patients treated
initially with placebo up to 56 days after the last abatacept dose up to week 52.
‡Pneumocystis jirovecii infection (see text).
§Pyelonephritis (n=1), dyspnoea (n=1), erythrodermic psoriasis (n=1), transitional
cell carcinoma (n=1), plus the event of P. jirovecii infection in the double-blind
period. The event of erythrodermic psoriasis occurred following treatment with
topical corticosteroids and intramuscular dexamethasone in a female patient with
severe plaque psoriasis at baseline (PASI score=27.6); the patient had discontinued
earlier from the study due to lack of efficacy.
¶Gastroenteritis (n=1), P. jirovecii infection (n=1), prostate cancer (n=1),
transitional cell carcinoma (n=1), uterine leiomyoma (n=1), colitis (n=1), biliary
dilatation plus an AE of upper abdominal pain (n=1) and interstitial lung disease
(n=1).
AE, adverse event; ISR, injection-site reaction; PASI, Psoriasis Area and Severity
Index (range 0–72); RTI, respiratory tract infection; SAE, serious adverse event.

Figure 3 Proportion of patients achieving ACR20 response (ITT
analysis, actual data for early escape patients) over the combined
double-blind and open-label periods in the total population (A) and the
TNFi-naïve (B) and TNFi-exposed (C) subgroups. Error bars represent
95% CIs. For EE patients, measurements at weeks 20, 24, 28, 36 and
44 are actual measurements at weeks 4, 8, 12, 20 and 28 of openlabel abatacept treatment. The increase in the proportion of patients
with ACR20 response from week 16 to week 24 in the placebo group
reflects the mixed population of EE patients who received abatacept
between weeks 16 and 24 and non-EE patients who received placebo
at week 24. If there were missing data, patients were imputed as
non-responders, unless data were missing between two time points at
which the patient had a response, in which case response was imputed.
ACR20, ≥20% improvement in the American College of Rheumatology
criteria; EE, early escape; ITT, intent to treat; TNFi, tumour necrosis factor
inhibitor.
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higher ACR20 response at 24 weeks with abatacept treatment
versus placebo. Although numerical improvements in individual ACR core components were observed with abatacept
versus placebo at 24 weeks, the CIs were overlapping. Due to
the lack of significant effect on HAQ-DI response rates in the
total population, it was not possible to attribute significance to
lower-ranking outcomes in the statistical hierarchy. The efficacy
in joints was supported by mean improvements in DAS28 (CRP)
with abatacept versus placebo. In addition, disease improvement
was evident when placebo-treated patients switched to abatacept. Outcomes tended to be better in the TNFi-naïve versus
TNFi-exposed subgroups.
Across end points up to week 52, responses were maintained
or improved for patients who continued on abatacept, demonstrating the durability of effects and accrual of benefits over time
on some measures. For patients who switched from placebo to
open-label abatacept, it is possible that observed improvements
could at least partially be explained by patient awareness of
receiving active treatment, or a continuation of trends during
receipt of placebo, rather than a true treatment effect. However,
the similar ACR20 response rates at 44 weeks for patients who
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Table 3
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whom ~60% had prior exposure to TNFi agents. There were
trends towards benefits in other musculoskeletal measures, with
maximal effects seen in the TNFi-naïve patients. However, only
modest benefit was demonstrated for psoriatic skin lesions.
Abatacept was well tolerated with no new safety signals.
Contributors PM, ABG and DG were involved in the conception and design of the
study and interpretation of data. DvdH and MN were involved in the conception and
design of the study, acquisition of data and interpretation of data. OF was involved
in interpretation of data. SB was involved in the acquisition of data and the analysis
and interpretation of data. AJ was involved in the conception and design of the
study, acquisition of data and the analysis and interpretation of data. All authors had
full access to the study data, critically reviewed the manuscript and approved the
final version prior to submission and take responsibility for the integrity and accuracy
of the reported data.
Funding This study was funded by Bristol-Myers Squibb. Under the direction
of the authors, Sharon Gladwin of Caudex, Oxford, UK (funded by Bristol-Myers
Squibb) provided writing assistance for the development of this manuscript. Editorial
assistance was provided by Paul Wilmott of Caudex, funded by Bristol-Myers Squibb.
Sandra Overfield, Protocol Manager, Bristol-Myers Squibb assisted in initial design
and operational aspects of the study.
Competing interests PM reports receiving consulting fees from AbbVie, Amgen,
Bristol-Myers Squibb, Celgene, Corrona, Crescendo, Demira, Janssen, Lilly, Merck,
Novartis, Pfizer, Sun, UCB and Zynerba; and speaker fees from AbbVie, Amgen, BristolMyers Squibb, Celgene, Crescendo, Genentech, Janssen, Novartis, Pfizer and UCB.
ABG reports receiving consulting fees from Abbott Laboratories (AbbVie), Actelion,
Akros, Amgen, Astellas, Baxalta, Beiersdorf, Bristol-Myers Squibb, Canfite, Catabasis,
Celgene, Centocor (Janssen), Coronado, CSL Behring Biotherapies for Life, Dermipsor,
Genentech, GlaxoSmithKline, Incyte, Karyopharm, Kineta One, KPI Therapeutics, Lilly,
Meiji Seika Pharma, Mitsubishi Tanabe Pharma Development America, Novartis, Novo
Nordisk, Pfizer, Takeda, TEVA, UCB, Vertex and Xenoport; and research grants (paid to
Tufts Medical Center) from Abbott Laboratories (AbbVie), Amgen, Baxalta, Celgene,
Centocor (Janssen), Dermira, Levia, Lilly, Merck, Novartis, Pfizer and Xenoport. DvdH
reports receiving consultancy fees from Bristol-Myers Squibb and also consultancy
fees from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Celgene,
Daiichi, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche,
Sanofi and UCB (outside the submitted work). OF reports receiving grant support from
AbbVie, Bristol-Myers Squibb and Pfizer; and speaker fees from Celgene, Janssen,
Novartis and UCB. AJ is an employee of Bristol-Myers Squibb and reports holding
stock in Bristol-Myers Squibb. MN is an employee of Bristol-Myers Squibb. SB is an
employee of Bristol-Myers Squibb and reports holding stock in Bristol-Myers Squibb.
DG reports receiving grant support from Bristol-Myers Squibb to participate in this
study; in addition, she reports receiving grant support and fees from AbbVie, Amgen,
Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB.
Ethics approval Schulman Associates Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work
is properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the
article) 2017. All rights reserved. No commercial use is permitted unless otherwise
expressly granted.

References

1 Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical
features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14–ii17.
2 Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed
psoriatic arthritis in patients with psoriasis in European/North American dermatology
clinics. J Am Acad Dermatol 2013;69:729–35.
3 Lemos LL, de Oliveira Costa J, Almeida AM, et al. Treatment of psoriatic arthritis with
anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and
safety. Rheumatol Int 2014;34:1345–60.
4	Ramiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic
arthritis: a systematic literature review for the 2015 update of the EULAR
recommendations for the management of psoriatic arthritis. Ann Rheum Dis
2016;75:490–8.
5 Ungprasert P, Thongprayoon C, Davis JM. Indirect comparisons of the efficacy of
subsequent biological agents in patients with psoriatic arthritis with an inadequate
response to tumor necrosis factor inhibitors: a meta-analysis. Clin Rheumatol
2016;35:1795–803.

Mease PJ, et al. Ann Rheum Dis 2017;76:1550–1558. doi:10.1136/annrheumdis-2016-210724

1557

Ann Rheum Dis: first published as 10.1136/annrheumdis-2016-210724 on 4 May 2017. Downloaded from http://ard.bmj.com/ on 29 June 2018 by guest. Protected by copyright.

started on abatacept and those who switched from placebo to
abatacept indicate a treatment effect and benefit after switching.
Skin responses to abatacept were modest. A small treatment
effect on skin manifestations has previously been observed with
the T-cell inhibitor, alefacept, in a phase III study in psoriasis.34
It is also possible that a higher dose of abatacept may be required
for optimal efficacy in skin versus musculoskeletal symptoms,
similar to previous findings with the TNFi etanercept.35
Caution is advised when comparing the current efficacy data
with findings from studies of TNFi and other agents in PsA.
The ACR20 response rate at week 24 in this study was lower
than that in previous studies of agents that target some of the
known effector molecules in PsA.36–38 However, this study
included a higher proportion of TNFi failures compared with
most studies,36 37 which may indicate a more treatment-refractory population, as noted previously.39 Higher efficacy in the
TNF-naive compared with the TNFi-exposed subgroup across
multiple end points in the current study confirmed the treatment resistance in the latter subpopulation. In contrast to findings with other agents with different mechanisms of action,36–38
abatacept treatment demonstrated better efficacy on musculoskeletal versus skin end points. The reasons for this are unclear
but may include differential dose requirements for optimal efficacy of abatacept in skin versus the joints, for example, due to
less efficient drug penetration of skin versus synovial tissue, and
distinct pathologies with divergent roles of T cells and T-cell
subsets in skin versus synovial inflammation in PsA. Regarding
the latter, it is interesting to note that, in PsA, agents targeting
the IL-23/IL-17 axis can achieve complete clearing of psoriatic
skin lesions without a similar level of efficacy in the joints.40
We speculate that T-cell subsets driving pathology in the skin
and joints may differ in their expression of CD28 and, hence,
susceptibility to abatacept.
In this study, subcutaneous abatacept was well tolerated with
no new safety signals, consistent with the phase II study of
intravenous abatacept in PsA15 and previous studies of subcutaneous and intravenous abatacept in RA.41 Throughout the
study, one serious opportunistic infection was reported. This
case of P. jirovecii infection occurred in the abatacept arm in
a patient who had a history of smoking and chronic obstructive pulmonary disease and had recently received high doses of
corticosteroids. It has been recognised that patients with chronic
obstructive pulmonary disease have an increased prevalence of
Pneumocystis colonisation, which may predispose them to acute
infection.42
Limitations of this study include the prespecified imputation
method used to measure radiographic progression. Imputation
as radiographic progressors of patients who escaped early to
open-label abatacept, based on poor clinical response at week
16, led to a relatively high imputed rate of structural progression at week 24 in both groups. This imputation method that
was designed initially is inappropriate as it assumed that the
structural radiographic data behaved similarly to clinical data
and obscured underlying rates of radiographic change. Overall,
there was minimal progression based on the mean change from
baseline in PsA-modified total SHS score over 24 and 44/52
weeks in both groups, making it difficult to detect meaningful
treatment differences. In this context, it should be noted that, in
the phase II study in PsA, abatacept demonstrated greater inhibition of structural damage versus placebo as well as improvements in joint inflammation on MRI over the same timeframe
(24 weeks).15
In summary, abatacept treatment achieved the primary
end point in ACR20 response rates in patients with PsA, of

Clinical and epidemiological research

1558

24 Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic
arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48–53.
25 Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite
disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272–7.
26 Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite
disease activity and responder indices for psoriatic arthritis (GRACE project). Ann
Rheum Dis 2013;72:986–91.
27 Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for
assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441–7.
28 Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
Conceptual framework and item selection. Med Care 1992;30:473–83.
29 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical
measure for routine clinical use. Clin Exp Dermatol 1994;19:210–6.
30 van der Heijde D, Sharp J, Wassenberg S, et al. Psoriatic arthritis imaging: a review of
scoring methods. Ann Rheum Dis 2005;64(Suppl 2):ii61–ii64.
31 Benham H, Norris P, Goodall J, et al. Th17 and Th22 cells in psoriatic arthritis and
psoriasis. Arthritis Res Ther 2013;15:R136.
32 Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+ T cells are enriched in the
joints of patients with psoriatic arthritis and correlate with disease activity and joint
damage progression. Arthritis Rheumatol 2014;66:1272–81.
33 Scarsi M, Zanotti C, Chiarini M, et al. Reduction of peripheral blood T cells producing
IFN-γ and IL-17 after therapy with abatacept for rheumatoid arthritis. Clin Exp
Rheumatol 2014;32:204–10.
34 Lebwohl M, Christophers E, Langley R, et al. An international, randomized, doubleblind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with
chronic plaque psoriasis. Arch Dermatol 2003;139:719–27.
35 Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens
for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind
multicentre trial. BMJ 2010;340:c147.
36 Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis
in a phase 3 randomised, placebo-controlled trial with apremilast, an oral
phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020–6.
37 McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE
2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
2015;386:1137–46.
38	Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40
monoclonal antibody, Ustekinumab, in patients with active psoriatic arthritis despite
conventional non-biological and biological anti-tumour necrosis factor therapy:
6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990–9.
39 Kavanaugh A, McInnes IB, Mease PJ, et al. Efficacy of subcutaneous secukinumab in
patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor
use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol
2016;43:1713–7.
40 Johnsson HJ, McInnes IB. Interleukin-12 and interleukin-23 inhibition in psoriatic
arthritis. Clin Exp Rheumatol 2015;33:S115–S118.
41 Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis.
Rheumatology 2013;52:986–97.
42 Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin
Microbiol Rev 2012;25:297–317.

Mease PJ, et al. Ann Rheum Dis 2017;76:1550–1558. doi:10.1136/annrheumdis-2016-210724

Ann Rheum Dis: first published as 10.1136/annrheumdis-2016-210724 on 4 May 2017. Downloaded from http://ard.bmj.com/ on 29 June 2018 by guest. Protected by copyright.

6 Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis
Res Ther 2009;11:214.
7 Cutolo M, Nadler SG. Advances in CTLA-4-Ig-mediated modulation of inflammatory
cell and immune response activation in rheumatoid arthritis. Autoimmun Rev
2013;12:758–67.
8 Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell
activation antigen B7. J Exp Med 1991;174:561–9.
9 Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory
to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114–23.
10 Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with
methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med
2006;144:865–76.
11	Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic
arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet
2008;372:383–91.
12 Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab
vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebocontrolled study in patients with rheumatoid arthritis and an inadequate response to
methotrexate. Ann Rheum Dis 2008;67:1096–103.
13 Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of
abatacept in patients with rheumatoid arthritis who underwent a washout after antitumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE
trial. Ann Rheum Dis 2009;68:1708–14.
14 Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept
in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic
factors. Ann Rheum Dis 2009;68:1870–7.
15 Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients
with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind,
placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939–48.
16 Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus
intravenous abatacept: a phase IIIb noninferiority study in patients with an
inadequate response to methotrexate. Arthritis Rheum 2011;63:2854–64.
17	Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis:
development of new criteria from a large international study. Arthritis Rheum
2006;54:2665–73.
18 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary
definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
19 Wells G, Becker JC, Teng J, et al. Validation of the 28-joint disease activity score
(DAS28) and European League against Rheumatism response criteria based on
C-reactive protein against disease progression in patients with Rheumatoid arthritis,
and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann
Rheum Dis 2009;68:954–60.
20 Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment
of existing measures and development of an instrument specific to psoriatic arthritis.
Arthritis Rheum 2008;59:686–91.
21 Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for
dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32:1745–50.
22 Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health
assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789–93.
23 Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid.
Dermatologica 1978;157:238–44.

